🔵 AQP1 Promoter Variant, Water Transport, and Outcomes in Peritoneal Dialysis
AQP1 Promoter Variant, Water Transport, and Outcomes in Peritoneal Dialysis
🔵 NATIVE A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
In this phase 2b trial involving patients with active NASH, the percentage of patients who had a decrease of at least 2 points in the SAF-A score without worsening of fibrosis was significantly higher with the 1200-mg dose of lanifibranor than with placebo. These findings support further assessment of lanifibranor in phase 3 trials.
🔵 Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
In this prospective study involving patients with NAFLD, fibrosis stages F3 and F4 were associated with increased risks of liver-related complications and death.
Covid19 🔵 Covid-19 Vaccination during Pregnancy and First-Trimester Miscarriage
Our study found no evidence of an increased risk for early pregnancy loss after Covid-19 vaccination and adds to the findings from other reports supporting Covid-19 vaccination during pregnancy.